SciSparc Ltd(SPRC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 28 at 7:30 PM ET (Korea 9/29 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -231.49 | Insider Own | 1.85% | Shs Outstand | 0.6M | Perf Week | 8.39% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -4.17% | Shs Float | 0.6M | Perf Month | -25.83% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 9.38% | Short Float | 1.96% | Perf Quarter | -12.48% |
| Income | -0.01B | P/S | 3.28 | EPS this Y | - | Inst Trans | 13.75% | Short Ratio | 0.06 | Perf Half Y | 25.58% |
| Sales | 0.00B | P/B | 0.05 | EPS next 5Y | - | ROA | -135.56% | Short Interest | 0.01M | Perf YTD | -59.89% |
| Book/sh | 104.4 | P/C | 0.61 | EPS past 3/5Y | 31.81% -13.87% | ROE | -196.55% | 52W High | -92.32% ($63.90) | Perf Year | -87.25% |
| Cash/sh | 8.03 | P/FCF | - | Sales past 3/5Y | -14.03% - | ROIC | -287.31% | 52W Low | 64.77% ($2.98) | Perf 3Y | -99.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.59% | Gross Margin | 46.38% | Volatility(W/M) | 10.54% 8.39% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | -0.6 | Sales Y/Y TTM | -34.46% | Oper. Margin | -1022.08% | ATR (14) | 0.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.38 | EPS Q/Q | - | Profit Margin | -1422.78% | RSI (14) | 42.69 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.41 | Sales Q/Q | - | SMA20 | -3.33% ($5.08) | Beta | 2.53 | Target Price | - |
| Payout | - | Debt/Eq | 0.09 | Earnings | - | SMA50 | -17.21% ($5.93) | Rel Volume | 0.04 | Prev Close | $5.21 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -28.54% ($6.87) | Avg Volume(3M) | 0.19M | Price | $4.91 |
| IPO | 2021/8/30 | Option/Short | No/Yes | Trades | 167 | Volume | 6,565 | Change | -5.76% |
A clinical-stage pharmaceutical company developing therapeutics for neurological and psychiatric disorders using complex formulations based on cannabinoids and palmitoylethanolamide (PEA). Its lead candidate, SCI-110, targets Tourette's syndrome, sleep apnea, and Alzheimer's disease, among other conditions. This Israeli micro-cap company operates its clinical assets through its subsidiary, Neurotera Labs.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual That is 4% of its average volume.
SPRC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $328. Peers typically go for $1,227.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.4%.
Tap to view numbers
It ranks #574 of 592 in the industry
Based on market cap of $3M.
FAQ
What kind of company is SPRC?
SPRC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SPRC?
The market cap of SPRC is approximately $3M, ranking 5,801 within its sector.
What is the 52-week high and low for SPRC?
SPRC has recorded a 52-week high of $63.90 and a low of $2.98.
